Group items tagged

New Lamotrigine Desitin 10mg/ml Oral Suspension is the first licensed Lamotrigine oral liquid medicine available in the UK, offering simple, accurate and flexible dosing for vulnerable patient groups with epilepsy and bi-polar disorder. Accurate dosing and slow titration are essential when initially prescribing for patients with epilepsy. This helps minimise the risk of potentially life-threatening side effects such as Stevens-Johnson syndrome (an acute, rare, and occasionally fatal skin reaction). Dose escalation is required every 2 weeks until the optimal dose is achieved to reach the desired maintenance level. Lamotrigine Desitin 10mg/ml Oral Suspension helps simplify complex prescribing and dispensing regimes, as all dosing requirements are covered in a single product. The supplied dosing syringe and cup make it simple for patients to use and carers to administer. The licensed Oral Suspension is likely to be of benefit when prescribing for children (over 2 years), older people (particularly patients with dysphagia) and also those with learning disabilities. The 10mg/ml strength simplifies accurate dosing for children and offers complete flexibility when dosing is based on mg/kg body weight.

The NHS Covid-19 vaccination programme has administered more than 40 million second doses following a bumper week that saw over 200,000 people coming forward for their second jab. Last week, more than 65,000 people aged 18 and over also stepped up to get their first dose of the Covid-19 jab. The NHS continued to encourage people to come forward for their first, second or third doses. Recent data from the UK Health Security Agency (UKHSA) showed that two doses of the vaccine are not enough to avoid the Omicron infection, but a booster significantly increases protection against the variant. Since the start of vaccination programme, NHS England has administered more than 113 million jabs in total. However, more than 1.1 million people aged 18 and over have still not come forward for their second dose.

A fourth dose of Covid-19 vaccine is not needed at present, as latest data shows first booster provides high levels of protection against Omicron variant among older adults, says the Joint Committee on Vaccination and Immunisation (JCVI). After analysing latest data from the UK Health Security Agency (UKHSA), JCVI said: "There is no immediate need to introduce a second booster dose, or fourth jab, to the most vulnerable". Data from UKSHA revealed that single booster dose provides around 90 per cent protection against hospitalisation to those aged 65 and over, even after three months of jab. However, protection against mild symptomatic infection is short-lived and drops to around 30 per cent by about three months. The study, which looked at booster doses in those aged over 65, showed that with two vaccine doses, protection against the infection drops to around 70 per cent after three months and to 50 per cent after six months.

The Department of Health and Social Care (DHSC) has suggested Estradiol patch as an alternative for patients who use 1 pump of Oestrogel daily. DHSC has updated Annex A of SSP022 and SSP023 for Oestrogel Pump-Pack 0.06 per cent gel to include a dose conversion to a specific alternative Estradiol patch. Previously, only dose conversions for patients using 2 to 4 pumps daily were included in Annex A of SSP022 and SSP023. Separately, the supporting guidance for three SSPs which allow quantity restriction have been updated to reflect the requirement to endorse the reduced quantity supplied in accordance with these SSPs. SSP019 - Oestrogel pump-pack 0.06% gel SSP020 - Ovestin 1mg cream SSP021 - Premique low dose 0.3mg/1.5mg modified release tablets "When endorsing an SSP for a reduced quantity, contractors must ensure that the correct SSP number is endorsed along with the product name and the reduced quantity supplied in accordance with the SSP," said PSNC.

Amgen's experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday (December 3). The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug, currently known as AMG133. Amgen shares have gained about 5% since the company said on Nov. 7 that 12 weeks of trial treatment at the highest monthly dose of AMG133 resulted in mean weight loss of 14.5%. At 150 days after the last dose, maintained weight loss had dropped to 11.2% below original weight at the start of the trial, according to findings detailed at a meeting of World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease in Los Angeles. Patients treated with AMG133 did have side effects including nausea and vomiting, but most cases were mild and resolved within a couple of days after the first dose, Amgen said.

The Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday authorised a Covid-19 vaccine for infants as young as six months, opening the door for vaccinating the country's youngest children once the UK's Joint Committee on Vaccination and Immunisation (JCVI) agrees. The regulator authorised the vaccine - made by Pfizer and BioNTech - for children aged six months to four years old, after it was deemed safe and effective based on an ongoing clinical trial involving 4,526 participants. Whether the vaccine is eventually deployed in this age group depends on a recommendation from the JCVI, which advises UK health departments on which shots should be used as part of the national vaccination programme. The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years. It is given as three injections in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.

Health authorities in India have said that Biological E's Covid-19 vaccine Corbevax can be administered as a booster dose in people who have taken the country's other two main shots, Covaxin and AstraZeneca's Covishield, from Friday (Aug 12). Corbevax will be available to over 18s as precautionary booster six months after a second dose, the health ministry said in an August 8 letter to state authorities. Covishield is produced for the Indian market by the Serum Institute of India under licence from AstraZeneca, while Bharat Biotech makes Covaxin. India has so far administered more than 2 billion Covid vaccine shots, including 113 million boosters, all of which have so far been of the same vaccine as the recipient's first two doses. The government says about 89 per cent of Indians above the age of 12 have had two doses.

If you want to start your day feeling refreshed and energized, consider creating a daily regimen of ginger shots instead! Ginger shots are like taking ginger ale straight to the source. They give you all sorts of vitamins, minerals, and antioxidants your body needs to feel its best. These shots are beverages made from concentrated doses of ginger root (Zingiber officinale), which are asserted to aid in warding off sickness and strengthen your resilience against many health conditions. However, ginger shots just became prevalent recently in the wellness society; ginger brews have been used since ancient times to cure a host of ailments. While ginger presents unique health features, you may wonder whether sipping ginger shots is healthful. This article inspects ginger shots, including their potential health benefits, side effects, and preparation at home. Ginger Shots Ginger shots are potent drinks made with fresh ginger root. The ingredients used in the shot differ depending on the recipe you want to try. Some shots include only fresh ginger juice, while others comprise lemon juice, orange juice, turmeric, cayenne pepper, and/or manuka honey. You can make it at home by squeezing fresh ginger root juice or blending fresh, grated ginger with different juices, like lemon or orange. Now you can see that these shots are available pre-made or made to take away at juicers or health food stores. You can also beat them up at home by operating a juicer machine. For this, just add freshly grated ginger to citrus juice or mix a dash of ginger with other ingredients in a high-powered blending pot. You may find ginger shots spicy and unpleasant to drink owing to their high content of ginger roots. Hence, they're made in small amounts and generally drunk in one or two swigs. Ginger Root Ginger root has been used medicinally for thousands of years. The ancient Chinese used it to treat stomach problems, colds, and inflammation. According to the National Institute of Health (NIH

We cannot deny the benefits and uses of regenerative medicines as they have been so in demand in recent times. One such effective medicine with a lot of potential health benefits is BPS-157. The peptide is thought to be extremely beneficial for those struggling with various neurological or health issues. Another medicine with the same beneficial effects is the Semax peptide. Well, the benefits of both these peptide-based medicines and their other aspects will be discussed in detail in this blog along with answering your question about the BPC-157 buy, Semax effects, and polypeptide. ALL ABOUT BPC-157: BPC-157, a pentadecapeptide consisting of 15 amino acids, is a synthetic peptide that is known for its positive effects on the human body. The peptide is derived from human gastric juice. A protein is present in the human gastric juice through which this peptide is derived and synthesized. It is called a Body Protection Protein as it exerts several therapeutic effects on the human body. Not only have health benefits or therapeutic effects, the peptide has healing and regeneration powers. It also helps in the preventing formation of gastric ulcers. This peptide is of great interest to researchers due to its numerous positive effects and benefits. DOSING LEVELS OF BPC-157: Not much about the dosing levels of BPC-157 has been researched yet but always try to concern the relevant persons before taking the medicine. The dosage of BPC-157 depends on the health and body conditions of the person taking it along with other related factors.

National Institute of Health and Care Excellence (NICE) has not recommended 'Tirzepatide', also known as Mounjaro, developed by Eli Lilly, in its draft guidance issued on Tuesday (27 June) for treating type 2 diabetes in adults alongside diet and exercise. The independent NICE committee recognised the importance of new treatment options given that fewer than two-thirds of the adults with type 2 diabetes have adequate glucose control when using current treatment options. Evidence submitted to the committee from clinical trials showed the use of tirzepatide at any dose resulted in better glucose control and lower weight compared with semaglutide or insulin therapy. The weight reduction was more pronounced with higher doses of tirzepatide, while the effect on glucose levels seemed less dose-dependent. Similar effects were observed against all GLP-1 receptor agonists in company's network meta-analysis, but this was uncertain. The committee have asked the company to provide more data to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.

To help manage the ongoing supply disruptions, the health regulators have extended to 28 October 2022, serious shortage protocols (SSPs) for 12 of the 13 hormone replacement therapies (HRT). "The only HRT SSP set to expire on 29 July 2022 is for SSP021 Premique low dose 0.3mg/1.5mg modified-release tablets. After 29 July, there will be no need to restrict quantities of Premique tablets as its supply situation has now stabilised," said PSNC. In addition, the dose equivalence advice and endorsement guidance for SSP024 and SSP025 have been updated. SSP024 and SSP025 have been updated by DHSC to provide greater clarity to pharmacists on the dose equivalences to determine the appropriate quantity to supply. Pharmacists are asked to refer to the latest SSP versions and endorsement guidance published on NHSBSA's website.

A new study has revealed that the risk of death from COVID-19 decreases significantly after vaccination, but this protection diminishes after six months, providing evidence for continued booster doses. Researchers from the UK Health Security Agency (UKHSA), who analysed more than 10 million cases of COVID-19 in adults in England between May 2020 and February 2022, found a clear association between vaccination and reduced mortality. But they also highlighted a crucial timeframe - within six months of the last vaccine dose - when Case Fatality Risk (CFR) - the proportion of cases that resulted in death - was consistently at its lowest across all age groups. After this, the protective benefit of the vaccine began to wane and CFR increased.

To curb the supply issue of HRT medicine, the government has taken a further action by issuing SSPs for Oestrogel, Ovestin cream, Lenzetto transdermal spray and Sandrena gel sachets - with appropriate alternatives. The move aims to allow community pharmacists to supply specified alternatives to the prescribed HRT products without needing to seek authorisation from the clinician who has prescribed the medicine. The regulator said that the availability of Premique Low Dose has impoved 'thanks to SSPs issued on 29 April to restrict dispensing for Oestrogel, Ovestin and Premique Low Dose to three months' supply'. "Since these measures were implemented, further deliveries of all three products have been made, with Premique Low Dose returning to good availability this week. The manufacturers of Oestrogel and Ovestin, as well as suppliers of alternative HRT products, are taking action to increase UK supply." It added, "SSPs restricting prescriptions to a maximum of three months' supply will also be issued for substitute products, as a precautionary measure to ensure the supply of those substitutes is maintained."

Have you ever wondered about the health benefits of ginseng? It's been used for thousands of years by people in Asia and Eastern Europe, but did you know it's good for more than just boosting energy? The ginseng plant deals with 11 combinations of short, slowly growing plants with fleshy roots. It can revive and improve well-being. This article will explore how this herbal plant can benefit your body. 11 Health Benefits of the Ginseng Plant There are two types of ginseng plants mainly: Asian or Korean ginseng (Panax ginseng) American ginseng (Panax quinquefolius). Studies have discovered that the distinct types have various uses. American ginseng is believed to be less stimulating in traditional Chinese medicine than the Asian one. There are several other herbs known as ginseng, like eleuthero or Siberian ginseng, but they don't have the valuable content of ginsenosides. Ginseng has traditionally been used for several medical illnesses. However, its benefits for most of them have yet to be thoughtfully researched. These include: 1/11_It may help your lungs work better. ginseng plant lowers lungs infections.Ginseng may also help your lungs, according to a published study in the Journal of Ethnopharmacology. Researchers found that one of the active ingredients in ginseng, ginsenoside Rg1 has an anti-inflammatory effect on the lungs and can even protect against asthma and bronchitis. They found that rats with asthma had less inflammation after being given doses of ginseng for two weeks compared to rats not given any. They also observed that rats with pneumonia had fewer symptoms when they were treated with inhaled doses of ginsenoside Rg1 or orally administered doses of Korean red ginseng extract (KRGE). 2/11_It may lower blood sugar levels. ginseng plant lower blood sugar levels. It's not just your imagination-ginseng can help lower blood sugar levels in people with diabetes. It also has been proven to reduce the amount of cholesterol in your body. It

A change in medication can benefit patients on blood pressure-lowering therapies significantly more than increasing the dose of their current medication. A recent study from Uppsala University that was published in the Journal of the American Medical Association (JAMA) demonstrates this. In this study, four different blood pressure-lowering medications were tested out on 280 individuals over the course of a year. "The effect of a change of medication can be twice as great as the effect of doubling the dose of the patient's current medication. It was clear in our study that certain patients achieved lower blood pressure from one drug than from another. This effect is large enough to be clinically relevant," said Johan Sundstrom, cardiologist and Professor of Epidemiology at Uppsala University, who is the first author of the study. Most Swedes develop high blood pressure sooner or later; more than two million Swedes have high blood pressure at the present time. Only a fifth of them have managed to bring their blood pressure under control through drug therapy, and some studies suggest that only half of them take their blood pressure medication as intended. Could this be because the efficacy and side-effects of the drugs differ from individual to individual?

Precise Shapes the radiation beam to match the exact contour of the tumour or lesion, ensuring the maximum prescribed dose of high-energy radiation is delivered to the entire tumour Protects surrounding healthy tissue Adapts the treatment beam to breathing and other body movements to continuously maintain safe, complete and accurate dose delivery

Britain's booster programme for Covid-19 vaccinations is set to be expanded following advice from scientists. The government's Joint Committee on Vaccination and Immunisation (JCVI) said today (November 15) that all healthy adults aged 40-49 should be offered a booster, six months after their second dose. Previously, the booster programme was limited to those aged 50 and over, and the clinically vulnerable. So far, some 12.6 million people have had a booster dose. The latest advice comes after the UK Health Security Agency released data from a real-world study which found the booster gave over 90 per cent protection against symptomatic Covid-19 for people aged 50 years and older.

Oxford Cannabinoid Technologies Holdings plc, which specialises in developing cannabis-derived medicines with pain-relieving properties, has successfully administered the first-in-human dose of its lead pharmaceutical drug compound, OCT461201, in its phase 1 clinical trial. The company holds a portfolio of four drug candidates intended for use as licensed pain medications. The drug is a selective cannabinoid receptor type 2 agonist with the potential to treat chemotherapy-induced peripheral neuropathy and irritable bowel syndrome. The UK trial, conducted by Simbec Research Limited, part of Simbec-Orion Group Ltd., is progressing with healthy volunteers, OCTP said in a statement. Using a single ascending dose protocol, the primary objective is to demonstrate OCT461201's safety and tolerability, while providing information on its pharmacokinetic profile, to confirm its value as a potential drug. Results from the trial, funded entirely by OCTP's existing resources, are expected in the third quarter of 2023, the statement added.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution developed by Danish specialist LEO Pharma. This injectable solution contains 300 mg of tralokinumab in a 2 mL pre-filled pen and will be available for tralokinumab patients in the UK from early 2024. Tralokinumab is indicated for treating moderate-to-severe atopic dermatitis in adult and adolescent patients aged 12 and older who require systemic therapy, Leo Pharma said in a statement. It is a fully human monoclonal antibody developed to specifically bind to and inhibit the IL-13 cytokine. Previously, it was available in a 150 mg in 1 mL pre-filled syringe. According to Leo Pharma, the 300 mg tralokinumab in a 2 mL pre-filled pen offers a streamlined administration for both patients and prescribers. It begins with an initial 600 mg dose in two injections, followed by a single 300 mg maintenance dose administered every other week. "We're pleased that this simplified administration method for tralokinumab will soon benefit eligible atopic dermatitis patients in the UK. It aligns with our commitment to elevate the standard of care and support for individuals with skin conditions," said Leanne Walsh, Vice President and General Manager of UK and Ireland at LEO Pharma.

Recent uptake of COVID-19 vaccine booster doses in Europe has been "rather disappointing," an official said on Thursday (November 24), amid concerns that protection against severe cases of the disease could weaken during the winter. The European average rate of re-vaccination, or receiving booster doses, was only 29 per cent in the groups of people considered to be at highest risk, such as the elderly and immunocompromised. "It is of concern that those most at risk of hospitalisation or severe COVID are not adequately protected," the European Medicines Agency's head of health threats and vaccines strategy, Marco Cavaleri, told a news briefing. Though there have not been major increases in COVID-19 case rates in recent weeks, Cavaleri said that could change during the colder winter months.